Skip to main content
Premium Trial:

Request an Annual Quote

Francis Collins to Step Down

Francis Collins, the director of the US National Institutes of Health, is to step down by the end of the year, Politico reports.

Collins was confirmed as NIH director in 2009 after being nominated to the post by President Barack Obama. He then stayed on at the position during the Trump Administration and into the Biden Administration. According to the Washington Post, Collins is the longest-serving NIH director, leading the agency for 12 years.

"I am proud of all we've accomplished. I fundamentally believe, however, that no single person should serve in the position too long, and that it's time to bring in a new scientist to lead the NIH into the future," Collins says in a statement.

During his tenure at NIH, the agency launched the Cancer Moonshot program and the All of Us Research Program, as well as worked with Moderna to develop a SARS-CoV-2 vaccine, the Post writes. At the same time, the agency had to deal with a deadly outbreak at its Clinical Center and work to boost diversity among the researchers it funds. Collins also tells the Post that the recent culture war over mask wearing and SARS-CoV-2 vaccination has been a "major heartbreak."

Prior to taking on the NIH director role, Collins served as the director of the National Human Genome Research Institute and oversaw the international effort to sequence the human genome, the Post notes. Politico adds that Collins plans return to his NIH lab to continue studying Type 2 diabetes and Hutchinson-Gilford Progeria Syndrome.

There has been no decision yet on an interim director, according to the Post.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.